Total Payments
$5,758
2024 Payments
$183.08
Companies
7
Transactions
15
Medicare Patients
781
Medicare Billing
$131,207
Payment Breakdown by Category
Research$4,704 (81.7%)
Other$481.79 (8.4%)
Food & Beverage$310.29 (5.4%)
Consulting$200.00 (3.5%)
Travel$62.00 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4,704 | 4 | 81.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $481.79 | 2 | 8.4% |
| Food and Beverage | $310.29 | 6 | 5.4% |
| Consulting Fee | $200.00 | 1 | 3.5% |
| Travel and Lodging | $62.00 | 2 | 1.1% |
Payments by Type
Research
$4,704
4 transactions
General
$1,054
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $4,724 | 5 | $0 (2019) |
| Boehringer Ingelheim International GmbH | $298.71 | 1 | $0 (2023) |
| Ipsen Pharma SAS | $200.00 | 1 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $183.08 | 1 | $0 (2024) |
| Exelixis Inc. | $176.46 | 3 | $0 (2017) |
| Advanced Accelerator Applications | $151.08 | 3 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $24.75 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $183.08 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($183.08) |
| 2023 | $298.71 | 1 | Boehringer Ingelheim International GmbH ($298.71) |
| 2019 | $695.05 | 2 | NOVARTIS PHARMACEUTICALS CORPORATION ($670.30) |
| 2018 | $1,492 | 5 | NOVARTIS PHARMACEUTICALS CORPORATION ($1,341) |
| 2017 | $3,089 | 6 | Novartis Pharmaceuticals Corporation ($2,713) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $183.08 | General |
| 10/13/2023 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $298.71 | General |
| 03/06/2019 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $24.75 | General |
| 01/17/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | AFINITOR (Drug) | — | In-kind items and services | $670.30 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: ONCOLOGY | ||||||
| 10/04/2018 | Advanced Accelerator Applications | LUTATHERA (lutetium Lu 177 dotatate) (Drug) | Food and Beverage | In-kind items and services | $93.86 | General |
| Category: Oncology | ||||||
| 10/04/2018 | Advanced Accelerator Applications | LUTATHERA (lutetium Lu 177 dotatate) (Drug) | Food and Beverage | In-kind items and services | $37.20 | General |
| Category: Oncology | ||||||
| 10/04/2018 | Advanced Accelerator Applications | LUTATHERA (lutetium Lu 177 dotatate) (Drug) | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: Oncology | ||||||
| 05/23/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | AFINITOR (Drug) | — | In-kind items and services | $670.80 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT • Category: ONCOLOGY | ||||||
| 01/19/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | SANDOSTATIN (Drug) | — | In-kind items and services | $670.30 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT • Category: ONCOLOGY | ||||||
| 04/04/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | AFINITOR (Drug) | — | In-kind items and services | $2,692.86 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT • Category: ONCOLOGY | ||||||
| 04/03/2017 | Ipsen Pharma SAS | — | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| 01/20/2017 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $104.22 | General |
| Category: Oncology | ||||||
| 01/20/2017 | Exelixis Inc. | Cabometyx (Drug) | Travel and Lodging | Cash or cash equivalent | $42.00 | General |
| Category: Oncology | ||||||
| 01/20/2017 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $30.24 | General |
| Category: Oncology | ||||||
| 01/18/2017 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $20.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $4,034 | 3 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $670.30 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 192 | 251 | $190,211 | $28,694 |
| 2022 | 3 | 183 | 255 | $196,487 | $30,719 |
| 2021 | 3 | 204 | 333 | $258,377 | $41,102 |
| 2020 | 4 | 202 | 310 | $234,070 | $30,692 |
Total Patients
781
Total Services
1,149
Medicare Billing
$131,207
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 119 | 174 | $134,502 | $21,370 | 15.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 28 | 28 | $30,380 | $3,790 | 12.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 31 | 33 | $19,041 | $2,705 | 14.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 16 | $6,288 | $829.64 | 13.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 121 | 187 | $144,551 | $23,158 | 16.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 25 | 25 | $27,125 | $3,991 | 14.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 37 | 43 | $24,811 | $3,569 | 14.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 135 | 255 | $197,115 | $32,204 | 16.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 32 | 32 | $34,720 | $4,997 | 14.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 37 | 46 | $26,542 | $3,900 | 14.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 133 | 236 | $182,428 | $23,555 | 12.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 28 | 28 | $30,380 | $4,156 | 13.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 29 | 34 | $19,618 | $2,424 | 12.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 12 | 12 | $1,644 | $557.64 | 33.9% |
About Dr. Emily Bergsland, MD
Dr. Emily Bergsland, MD is a Internal Medicine healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1295792729.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Emily Bergsland, MD has received a total of $5,758 in payments from pharmaceutical and medical device companies, with $183.08 received in 2024. These payments were reported across 15 transactions from 7 companies. The most common payment nature is "" ($4,704).
As a Medicare-enrolled provider, Bergsland has provided services to 781 Medicare beneficiaries, totaling 1,149 services with total Medicare billing of $131,207. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location San Francisco, CA
- Active Since 04/27/2006
- Last Updated 09/11/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1295792729
Products in Payments
- AFINITOR (Drug) $4,034
- SANDOSTATIN (Drug) $670.30
- Cabometyx (Drug) $176.46
- LUTATHERA (lutetium Lu 177 dotatate) (Drug) $151.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Francisco
Dr. Fred Cohen, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
John Teerlink, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Kenneth Binmoeller, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Dr. Hope Rugo, Md, MD
Internal Medicine — Payments: $881,117
Internal Medicine $881,117
Dr. Steven Harris, M.d, M.D
Internal Medicine — Payments: $806,637
Internal Medicine $806,637
Dr. Kenneth Colley, Md, MD
Internal Medicine — Payments: $732,736
Internal Medicine $732,736